Developer docs
API playgroundTry for free, no card

Search company profiles

Bioarchitech

Full company profile

uuid000n9ui

Namestring
Bioarchitech
Legal namestring
Bioarchitech Ltd
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Bioarchitech is a preclinical-stage immuno-oncology therapeutics company headquartered in Oxford, United Kingdom, founded in 2021 by Kevin Maskell, Geoff Hale, Lili Wang, and Hannah Chen. The company develops multifunctional cancer immunotherapies by mining the genetic code of viruses, with the explicit thesis that single-mechanism oncology drugs are insufficient to cure most patients. Its pipeline comprises two distinct assets: BA-V151, an intravenous modified Vaccinia virus engineered to selectively replicate within tumour cells and armed with a proprietary CD47-targeting single-domain antibody (sdAb) that blocks the "don't eat me" signal to enable immune phagocytosis (designed for metastatic cancer); and BA-R166, an intratumoural self-amplifying RNA (saRNA) immunotherapeutic that triggers immunogenic cell death and converts the tumour into an in-situ personalised vaccine prior to surgery (designed for early-stage solid tumours, initially oesophageal and lung cancer).

The platform rests on two differentiated technical components: a CD47-blocking sdAb expressed from within an oncolytic viral vector, which addresses the long-standing toxicity/efficacy trade-off of systemic CD47 blockade; and a saRNA delivery system that achieves full mechanism of action within approximately one to three days at vaccine-level cost. Preclinical proof-of-concept data for BA-V151 demonstrated complete protection in an aggressive metastasising cancer model versus 20–50% mortality in untreated controls, and the anti-CD47 sdAb has shown enhanced antibody-dependent cellular phagocytosis when combined with trastuzumab (Herceptin®). Both candidates are protected by UK patent applications filed in January 2025.

Bioarchitech currently generates no commercial revenue. Its go-to-market model centres on biopharma licensing, co-development, and contract manufacturing organisation (CMO) partnerships, supported by participation in industry partnering events (JPM Biotech Showcase, BioTrinity, ChinaBio, Oncolytic Virotherapy Summit). The end beneficiaries, if approved, would be oncology patients with metastatic disease (BA-V151) or early-stage solid tumours at risk of spreading (BA-R166). The company operates from the Oxford Trust's Wood Centre for Innovation and has secured a UKHSA/ECACC material license to develop a scalable manufacturing platform for BA-V151.

Short descriptiontext

Bioarchitech is a preclinical-stage Oxford-based immuno-oncology biotech developing two multifunctional cancer immunotherapies: BA-V151 (an oncolytic Vaccinia virus blocking CD47 for metastatic cancer) and BA-R166 (an intratumoural self-amplifying RNA neoadjuvant for early-stage solid tumours prior to surgery).

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersOxford, United Kingdom
HQ citystring
Oxford
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncolytic virus therapy, cancer immunotherapy, self-amplifying RNA therapeutics, viral vector biopharmaceuticals, immuno-oncology pipeline
Industry2 codes
PRIMARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Cancer Immunotherapy Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Therapeutic pipeline development and out-licensing
TypeOne Time License
Description

As a preclinical-stage immuno-oncology biotech, Bioarchitech has no current commercial revenue. The company is advancing BA-V151 and BA-R166 through preclinical and towards clinical development, with the intention of out-licensing or co-developing assets with pharmaceutical partners, or pursuing independent commercialisation upon clinical validation.

bioarchitech.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Others, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Bioarchitech is a preclinical-stage immuno-oncology biotechnology company engineering multifunctional cancer immunotherapies by mining the genetic code of viruses. Its two pipeline assets are BA-V151, an intravenous modified Vaccinia virus armed with a proprietary anti-CD47 single-domain antibody for metastatic cancer, and BA-R166, an intratumoural self-amplifying RNA (saRNA) immunotherapeutic designed as a neoadjuvant to turn early-stage tumours into personalised vaccines prior to surgery.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • In proof-of-concept experiments, BA-V151 achieved complete protection in an aggressive metastasising cancer model where 20–50% of untreated animals typically die from metastases.
+2 more records
Product overview1 text field

Bioarchitech is developing two distinct cancer immunotherapy assets as part of its pipeline: BA-V151 is an intravenous viral therapy using a modified Vaccinia virus engineered with a proprietary anti-CD47 single-domain antibody, designed for metastatic cancers with comprehensive systemic reach; BA-R166 is a direct intratumoural injection of self-amplifying RNA that acts as a neo-adjuvant immunotherapy, turning tumours into personalised in-situ vaccines prior to surgery for early-stage cancers. Both candidates are multifunctional immunotherapies that both kill cancer cells and induce immunity against metastatic disease.

Product and service2 records
1BA-V151
2BA-R166
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1UK Health Security Agency (UKHSA) / ECACC
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-03-01
Description

Bioarchitech secured a material license from UKHSA's European Collection of Authenticated Cell Cultures (ECACC) for a mammalian cell line to be developed as a scalable, high-yield viral manufacturing platform and for the Vaccinia virus vector backbone of BA-V151. The licensed cell line is pre-adapted to suspension conditions, improving scalability over traditional adherent cell lines. Bioarchitech plans to further optimise the platform under serum-free growth conditions for regulatory suitability, then establish a research cell bank for transfer to a CMO partner for process development.

bioarchitech.com
2Engineering Biology Centre for Doctoral Training (EngBioCDT)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-01
Description

Bioarchitech acts as an industry partner for the EngBioCDT at the University of Oxford, integrating industry insights into academic training. Dr Andri Vasou delivered lectures on the immune system. Bioarchitech collaborates with Associate Professor Malavika Nair on short-term student research projects investigating innovative approaches to mRNA delivery, focusing on alternative delivery vehicles that improve efficacy and cancer targeting.

bioarchitech.com
Strategic tierMinorTypeOthers
Description

Listed as a partner on Bioarchitech's partners page. Likely provides patent/IP legal services.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Listed as a partner on Bioarchitech's partners page. Bioarchitech collaborates with University of Oxford researchers including Malavika Nair (EngBioCDT) and has academic founders with Oxford affiliations. The company is based at Oxford and leverages Oxford's research ecosystem.

Strategic tierMinorTypeOthers
Description

Listed as a partner on Bioarchitech's partners page. Associated with Oxford's technology and startup ecosystem.

6BioEscalator
Strategic tierMinorTypeOthers
Description

Listed as a partner on Bioarchitech's partners page. Bioarchitech was previously housed at the BioEscalator (Oxford's bioscience incubator) before moving to the Wood Centre for Innovation in July 2024.

bioarchitech.com
Strategic tierCoreTypeOthers
Description

Listed as a partner on Bioarchitech's partners page. The Oxford Trust operates the Wood Centre for Innovation (WCFI) where Bioarchitech is headquartered. Bioarchitech moved to WCFI in July 2024 for larger lab space to accommodate team expansion.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Commercial-stage mRNA company with a personalised cancer vaccine (mRNA-4157/V940 in Phase 3 with Merck). Broad incumbent competing for the personalised cancer vaccine value pool that BA-R166 is positioned to address via a cheaper, off-the-shelf intratumoural saRNA approach.

TypeDirect peer
Description

Clinical-stage immuno-oncology company developing a CD47-blocking therapeutic (evorpacept) with a differentiated high-affinity mechanism. Direct peer in the CD47 checkpoint space relevant to Bioarchitech's anti-CD47 sdAb payload on BA-V151.

TypeDirect peer
Description

Clinical-stage biotech developing self-amplifying RNA therapeutics for cancer and other diseases. Direct peer sharing the saRNA modality relevant to BA-R166 with a comparable preclinical-to-early-clinical stage profile.

TypeBroad incumbent
Description

Commercial-stage immuno-oncology and infectious disease mRNA company with FixVac, iNeST, and other cancer vaccine platforms (including the personalised neoantigen vaccine programme with Genentech). Broad incumbent relevant to BA-R166's personalised cancer vaccine thesis and to the broader oncolytic-immunotherapy space.

TypeDirect peer
Description

Imperial College London spin-out developing self-amplifying RNA vaccines for infectious disease and oncology. Direct peer to BA-R166 given shared saRNA modality and UK academic origin in the same broader RNA ecosystem.

TypeDirect peer
Description

Clinical-stage immuno-oncology company developing oncolytic vaccinia virus-based therapies (Olvi-Vec) delivered intravenously and intrapleurally for cancer. Direct peer given Bioarchitech's modified Vaccinia virus backbone (BA-V151) and intravenous delivery approach.

TypeDirect peer
Description

Clinical-stage biotech developing a portfolio of oncolytic viruses (RP1, RP2, RP3) based on an engineered herpes simplex virus platform for solid tumours. Directly comparable to Bioarchitech's BA-V151 as a viral-immunotherapy for cancer with mechanism of action combining direct oncolysis and immune activation.

TypeDirect peer
Description

Clinical-stage immuno-oncology company developing oncolytic virotherapy (VAXINIA / CF33) and B-cell immunotherapies for solid tumours. Direct peer through shared focus on oncolytic viral platforms for cancer immunotherapy with intratumoural and intravenous routes.

TypeDirect peer
Description

Clinical-stage mRNA medicines company with a self-amplifying RNA (saRNA) platform including oncology and infectious disease programs. Direct peer to BA-R166 as the most advanced saRNA developer, sharing the same core modality and cost/speed advantages.

TypeRegional player
Description

UK-based cell and gene therapy CDMO and developer with lentiviral vector manufacturing expertise. Regional peer given shared Oxford/UK biotech ecosystem, prior overlap with Bioarchitech alumni (Ines Loureiro), and relevance to viral vector manufacturing for BA-V151.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bioarchitech

Cancer Immunotherapy Biopharmaceuticalsbioarchitech.com

Bioarchitech is a preclinical-stage Oxford-based immuno-oncology biotech developing two multifunctional cancer immunotherapies: BA-V151 (an oncolytic Vaccinia virus blocking CD47 for metastatic cancer) and BA-R166 (an intratumoural self-amplifying RNA neoadjuvant for early-stage solid tumours prior to surgery).

What Bioarchitech does

Bioarchitech is a preclinical-stage immuno-oncology therapeutics company headquartered in Oxford, United Kingdom, founded in 2021 by Kevin Maskell, Geoff Hale, Lili Wang, and Hannah Chen. The company develops multifunctional cancer immunotherapies by mining the genetic code of viruses, with the explicit thesis that single-mechanism oncology drugs are insufficient to cure most patients. Its pipeline comprises two distinct assets: BA-V151, an intravenous modified Vaccinia virus engineered to selectively replicate within tumour cells and armed with a proprietary CD47-targeting single-domain antibody (sdAb) that blocks the "don't eat me" signal to enable immune phagocytosis (designed for metastatic cancer); and BA-R166, an intratumoural self-amplifying RNA (saRNA) immunotherapeutic that triggers immunogenic cell death and converts the tumour into an in-situ personalised vaccine prior to surgery (designed for early-stage solid tumours, initially oesophageal and lung cancer).

The platform rests on two differentiated technical components: a CD47-blocking sdAb expressed from within an oncolytic viral vector, which addresses the long-standing toxicity/efficacy trade-off of systemic CD47 blockade; and a saRNA delivery system that achieves full mechanism of action within approximately one to three days at vaccine-level cost. Preclinical proof-of-concept data for BA-V151 demonstrated complete protection in an aggressive metastasising cancer model versus 20–50% mortality in untreated controls, and the anti-CD47 sdAb has shown enhanced antibody-dependent cellular phagocytosis when combined with trastuzumab (Herceptin®). Both candidates are protected by UK patent applications filed in January 2025.

Bioarchitech currently generates no commercial revenue. Its go-to-market model centres on biopharma licensing, co-development, and contract manufacturing organisation (CMO) partnerships, supported by participation in industry partnering events (JPM Biotech Showcase, BioTrinity, ChinaBio, Oncolytic Virotherapy Summit). The end beneficiaries, if approved, would be oncology patients with metastatic disease (BA-V151) or early-stage solid tumours at risk of spreading (BA-R166). The company operates from the Oxford Trust's Wood Centre for Innovation and has secured a UKHSA/ECACC material license to develop a scalable manufacturing platform for BA-V151.

Bioarchitech firmographics

Firmographics
Name
Bioarchitech
Legal name
Bioarchitech Ltd
Website
https://bioarchitech.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
Bioarchitech is a preclinical-stage Oxford-based immuno-oncology biotech developing two multifunctional cancer immunotherapies: BA-V151 (an oncolytic Vaccinia virus blocking CD47 for metastatic cancer) and BA-R166 (an intratumoural self-amplifying RNA neoadjuvant for early-stage solid tumours prior to surgery).
Ownership category
akta.pro rank

Bioarchitech industry classification

Industry
Product category
Cancer Immunotherapy Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • Oncolytic virus therapy
  • Cancer immunotherapy
  • Self-amplifying RNA therapeutics
  • Viral vector biopharmaceuticals
  • Immuno-oncology pipeline

Where Bioarchitech is headquartered

Location

Headquarters

HQ city
Oxford
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Bioarchitech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Others, Infrastructure

Revenue model

  1. Therapeutic pipeline development and out-licensing: As a preclinical-stage immuno-oncology biotech, Bioarchitech has no current commercial revenue. The company is advancing BA-V151 and BA-R166 through preclinical and towards clinical development, with the intention of out-licensing or co-developing assets with pharmaceutical partners, or pursuing independent commercialisation upon clinical validation.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Bioarchitech product offering

Product offering

Core offering

Bioarchitech is a preclinical-stage immuno-oncology biotechnology company engineering multifunctional cancer immunotherapies by mining the genetic code of viruses. Its two pipeline assets are BA-V151, an intravenous modified Vaccinia virus armed with a proprietary anti-CD47 single-domain antibody for metastatic cancer, and BA-R166, an intratumoural self-amplifying RNA (saRNA) immunotherapeutic designed as a neoadjuvant to turn early-stage tumours into personalised vaccines prior to surgery.

Product overview

Bioarchitech is developing two distinct cancer immunotherapy assets as part of its pipeline: BA-V151 is an intravenous viral therapy using a modified Vaccinia virus engineered with a proprietary anti-CD47 single-domain antibody, designed for metastatic cancers with comprehensive systemic reach; BA-R166 is a direct intratumoural injection of self-amplifying RNA that acts as a neo-adjuvant immunotherapy, turning tumours into personalised in-situ vaccines prior to surgery for early-stage cancers. Both candidates are multifunctional immunotherapies that both kill cancer cells and induce immunity against metastatic disease.

Differentiator

Problem solved

Functional benefit

Products and services

  • BA-V151
  • BA-R166

Quantifiable outcome

  • In proof-of-concept experiments, BA-V151 achieved complete protection in an aggressive metastasising cancer model where 20–50% of untreated animals typically die from metastases.
  • +2 more outcomes

Companies that use Bioarchitech

Customer profile

Segments1 record

Ideal customer profiles1 record

Bioarchitech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Bioarchitech partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • UK Health Security Agency (UKHSA) / ECACCcoreTechnology or Integration · 1 March 2026Bioarchitech secured a material license from UKHSA's European Collection of Authenticated Cell Cultures (ECACC) for a mammalian cell line to be developed as a scalable, high-yield viral manufacturing platform and for the Vaccinia virus vector backbone of BA-V151. The licensed cell line is pre-adapted to suspension conditions, improving scalability over traditional adherent cell lines. Bioarchitech plans to further optimise the platform under serum-free growth conditions for regulatory suitability, then establish a research cell bank for transfer to a CMO partner for process development.
  • Engineering Biology Centre for Doctoral Training (EngBioCDT)coreStrategic or Co-development Partner · 1 October 2024Bioarchitech acts as an industry partner for the EngBioCDT at the University of Oxford, integrating industry insights into academic training. Dr Andri Vasou delivered lectures on the immune system. Bioarchitech collaborates with Associate Professor Malavika Nair on short-term student research projects investigating innovative approaches to mRNA delivery, focusing on alternative delivery vehicles that improve efficacy and cancer targeting.
  • Greaves BrewsterminorOthersListed as a partner on Bioarchitech's partners page. Likely provides patent/IP legal services.
  • University of OxfordcoreStrategic or Co-development PartnerListed as a partner on Bioarchitech's partners page. Bioarchitech collaborates with University of Oxford researchers including Malavika Nair (EngBioCDT) and has academic founders with Oxford affiliations. The company is based at Oxford and leverages Oxford's research ecosystem.
  • Oxford TechnologyminorOthersListed as a partner on Bioarchitech's partners page. Associated with Oxford's technology and startup ecosystem.
  • BioEscalatorminorOthersListed as a partner on Bioarchitech's partners page. Bioarchitech was previously housed at the BioEscalator (Oxford's bioscience incubator) before moving to the Wood Centre for Innovation in July 2024.
  • Oxford Trust (Wood Centre for Innovation)coreOthersListed as a partner on Bioarchitech's partners page. The Oxford Trust operates the Wood Centre for Innovation (WCFI) where Bioarchitech is headquartered. Bioarchitech moved to WCFI in July 2024 for larger lab space to accommodate team expansion.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Bioarchitech competitors and assessment

Company assessment

Broad incumbents

  • Moderna: Commercial-stage mRNA company with a personalised cancer vaccine (mRNA-4157/V940 in Phase 3 with Merck). Broad incumbent competing for the personalised cancer vaccine value pool that BA-R166 is positioned to address via a cheaper, off-the-shelf intratumoural saRNA approach.
  • BioNTech: Commercial-stage immuno-oncology and infectious disease mRNA company with FixVac, iNeST, and other cancer vaccine platforms (including the personalised neoantigen vaccine programme with Genentech). Broad incumbent relevant to BA-R166's personalised cancer vaccine thesis and to the broader oncolytic-immunotherapy space.

Direct peers

  • ALX Oncology: Clinical-stage immuno-oncology company developing a CD47-blocking therapeutic (evorpacept) with a differentiated high-affinity mechanism. Direct peer in the CD47 checkpoint space relevant to Bioarchitech's anti-CD47 sdAb payload on BA-V151.
  • Replicate Bioscience: Clinical-stage biotech developing self-amplifying RNA therapeutics for cancer and other diseases. Direct peer sharing the saRNA modality relevant to BA-R166 with a comparable preclinical-to-early-clinical stage profile.
  • VaxEquity: Imperial College London spin-out developing self-amplifying RNA vaccines for infectious disease and oncology. Direct peer to BA-R166 given shared saRNA modality and UK academic origin in the same broader RNA ecosystem.
  • Genelux Corporation: Clinical-stage immuno-oncology company developing oncolytic vaccinia virus-based therapies (Olvi-Vec) delivered intravenously and intrapleurally for cancer. Direct peer given Bioarchitech's modified Vaccinia virus backbone (BA-V151) and intravenous delivery approach.
  • Replimune: Clinical-stage biotech developing a portfolio of oncolytic viruses (RP1, RP2, RP3) based on an engineered herpes simplex virus platform for solid tumours. Directly comparable to Bioarchitech's BA-V151 as a viral-immunotherapy for cancer with mechanism of action combining direct oncolysis and immune activation.
  • Imugene: Clinical-stage immuno-oncology company developing oncolytic virotherapy (VAXINIA / CF33) and B-cell immunotherapies for solid tumours. Direct peer through shared focus on oncolytic viral platforms for cancer immunotherapy with intratumoural and intravenous routes.
  • Arcturus Therapeutics: Clinical-stage mRNA medicines company with a self-amplifying RNA (saRNA) platform including oncology and infectious disease programs. Direct peer to BA-R166 as the most advanced saRNA developer, sharing the same core modality and cost/speed advantages.

Regional players

  • OXB (formerly Oxford BioMedica): UK-based cell and gene therapy CDMO and developer with lentiviral vector manufacturing expertise. Regional peer given shared Oxford/UK biotech ecosystem, prior overlap with Bioarchitech alumni (Ines Loureiro), and relevance to viral vector manufacturing for BA-V151.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Bioarchitech social profiles

Digital presence

Bioarchitech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bioarchitech leadership team

Management profile

Number of profiles

Profiles8 records

Bioarchitech funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bioarchitech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bioarchitech

What does Bioarchitech do?

Bioarchitech is a preclinical-stage immuno-oncology biotechnology company engineering multifunctional cancer immunotherapies by mining the genetic code of viruses. Its two pipeline assets are BA-V151, an intravenous modified Vaccinia virus armed with a proprietary anti-CD47 single-domain antibody for metastatic cancer, and BA-R166, an intratumoural self-amplifying RNA (saRNA) immunotherapeutic designed as a neoadjuvant to turn early-stage tumours into personalised vaccines prior to surgery.

Is Bioarchitech a public or private company?

Bioarchitech is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Bioarchitech founded?

Bioarchitech was founded in 2021. It employs 1 to 10 people.

Where is Bioarchitech based?

Bioarchitech is headquartered in Oxford, United Kingdom, in the Europe region.

How does Bioarchitech make money?

One revenue line is on record: therapeutic pipeline development and out-licensing.

Who are Bioarchitech's main competitors?

Broad incumbents on record are Moderna and BioNTech. Direct peers are ALX Oncology, Replicate Bioscience, VaxEquity, Genelux Corporation, Replimune, Imugene and Arcturus Therapeutics. OXB (formerly Oxford BioMedica) is listed as a regional player.

Does Bioarchitech have an API?

No public API is recorded for Bioarchitech.

What industry is Bioarchitech in?

Bioarchitech's product category is Cancer Immunotherapy Biopharmaceuticals. Its primary akta.pro industry code is HLAAACAF, Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches), with a secondary code of HLAAADAA, mRNA Therapeutics (vaccines, protein replacement, immuno-oncology). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals